Form Type:  SC 13G
Filing Date:  1/31/2011 
CIK:  0001382911 
Address:  3344 N. TORREY PINES CT.
City, State, Zip:  LA JOLLA, California 92037 
Telephone:  (858) 875-8600 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
-0.01 (-6.45%)  
Trade Time: 
May 22  
Market Cap: 
Trade OREXQ now with

© 2018  
Description of Business
Orexigen® Therapeutics, Inc. ("Orexigen," "we," "our" and "us") is a biopharmaceutical company focused on the treatment of obesity. Our sole product, Contrave® (naltrexone HCl / bupropion HCl prolonged release), is approved in the United States by the U.S. Food and Drug Administration, or FDA, as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index, or BMI, of 30 kg/m 2 or greater (obese), or 27 kg/m 2 or greater (overweight) in the presence of at least one weight-related comorbid condition. Contrave is a combination of generic drug components, each of which has already received regulatory approval for other indications and has been commercialized in the United States and in a majority of the member countries of the European Union. In September 2014, the FDA approved our New Drug Application, or NDA, for Contrave.
Register and access this filing in:     
  EXHIBIT 99.1